SCA
CCXI

Snowden Capital Advisors’s ChemoCentryx, Inc. CCXI Stock Holding History

Snowden Capital Advisors’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-39
Closed -$1K – 2208
2021
Q4 		$1K Buy
+39
New +$1.37K ﹤0.01% 2020

Other funds holding CCXI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Snowden Capital Advisors's CCXI Position: Q1 2022 in Review

Snowden Capital Advisors sold out of ChemoCentryx, Inc. (CCXI) in Q1 2022, closing a stake of 39 shares — an estimated $1K sold.

Snowden Capital Advisors first reported a position in CCXI in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 176 funds tracked by Wall St. Rank hold CCXI as of Q1 2022.

  • Snowden Capital Advisors reported no remaining ChemoCentryx, Inc. position as of Q1 2022 after selling out during the quarter.
  • Snowden Capital Advisors sold 39 ChemoCentryx, Inc. shares in Q1 2022, an estimated $1K.
  • Snowden Capital Advisors first reported a position in ChemoCentryx, Inc. in Q4 2021 and held it in 1 quarter.
  • Snowden Capital Advisors's ChemoCentryx, Inc. position peaked at $1K in Q4 2021.
  • 176 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.